ESTABLISHMENT OF STABLE MOUSE HUMAN-HUMAN HYBRID CELL-LINES PRODUCING LARGE AMOUNTS OF ANTITETANUS HUMAN MONOCLONAL-ANTIBODIES WITH HIGH NEUTRALIZING ACTIVITY

被引：26

作者：

KAMEI, M ^{[1
]}

HASHIZUME, S ^{[1
]}

SUGIMOTO, N ^{[1
]}

OZUTSUMI, K ^{[1
]}

MATSUDA, M ^{[1
]}

机构：

[1] MORINAGA INST BIOL SCI,2-1-1 SHIMOSUEYOSHI,TSURUMI KU,YOKOHAMA,KANAGAWA 230,JAPAN

来源：

EUROPEAN JOURNAL OF EPIDEMIOLOGY | 1990年 / 6卷 / 04期

关键词：

HYBRID CELL LINES; ANTITETANUS MONOCLONAL ANTIBODIES; HUMAN MONOCLONAL ANTIBODIES; NEUTRALIZING ANTIBODIES;

D O I：

10.1007/BF00151713

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

To establish stable hybrid cell lines producing human anti-tetanus antibody with high toxin-neutralizing activity, peripheral lymphocytes from humans hyperimmunized with tetanus toxoid were, after in vitro antigen stimulation, fused with a mouse/human heteromyeloma or human lymphoblastoid cell line and cloned. Unlike the IgM secretors (six clones), the IgG secretors we obtained (six clones) produced anti-tetanus human monoclonal antibodies with high neutralizing activity (the highest one, cell line G2, 4.3 IU/100 mu-g IgG). Appropriate combinations of three or four kinds of monoclonal antibodies of the IgG type resulted in markedly increased neutralizing activity comparable with that of anti-tetanus human polyclonal immunoglobulin preparations currently used clinically on the basis of toxin-specific IgG content. Five of these cell lines produced 10 approximately 20 mu-g of antibody per ml for more than 3 months. The cell line G2 produced 6 mg of antibody per day in serum-free medium in a 500-ml bioreactor in perfusion culture and 13-104 mg in a nude mouse. These cell lines satisfied, for the first time, the minimal requirements for applying human monoclonal antibodies to clinical use.

引用

页码：386 / 397

页数：12

共 33 条

[11] Kozbor D., Roder J.C., Chang T.H., Steplewski Z., Koprowski H., Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma, Hybridoma, 1, pp. 323-328, (1982)
[12] Laemmli U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature, 227, pp. 680-685, (1979)
[13] Larrick J.W., Truitt K.E., Raubitschek A.A., Senyk G., Wang J.C.N., Characterization of human hybridomas secreting antibody to tetanus toxoid, Proc. Nall. Acad. Sci. USA, 80, pp. 6376-6380, (1983)
[14] Matsuda M., The structure of tetanus toxin, Botulinum Neurotoxin and Tetanus Toxin, pp. 69-92, (1989)
[15] Matsuda M., Sugimoto N., Ozutsumi K., Acute botulinum-like intoxication by tetanus toxin in mice and the localization of the acute toxicity in the N-terminal papain-fragment of the toxin, Proceedings of the 6th International Conference on Tetanus, pp. 21-32, (1982)
[16] Matsuda M., Yoneda M., Isolation and purification of two antigenically active, “complementary” polypeptide fragments of tetanus neurotoxin, Infect. Immun., 12, pp. 1147-1153, (1975)
[17] Matsuda M., Yoneda M., Antigenic substructure of tetanus neurotoxin, Biochem. Biophys. Res. Commun., 77, pp. 268-274, (1977)
[18] Miller R.A., Maloney D.G., Warnke R., Levy R., Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody, New England J. Med., 306, pp. 517-522, (1982)
[19] Miyazaki Y., Establishment of human monoclonal antibody reactive with B lymphoblastoid cell lines and Burkitt's lymphoma, Jpn. Soc. Immunol. Experimental Procedures in Immunology (ed.), Vol. 12, pp. 3975-3979, (1983)
[20] Mizuguchi J., Yoshida R., Sato Y., Nagaoka F., Kondo S., Matuhasi T., Requirements for at least two distinct monoclonal antibodies for efficient neutralization of tetanus toxin in vivo, Naturwissenschaften, 69, pp. 597-598, (1982)

← 1 2 3 4 →